NCT07234591

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Usynova Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

Conditions

• Plaque Psoriasis
• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Tyk2 inhibitor	Specific dose of Tyk2 inhibitor on specific days
DRUG	Placebo	Specified dose of Placebo on specified days.

Timeline

• Start date: 2025-10-21
• Primary completion: 2026-04-30
• Completion: 2026-05-30
• First posted: 2025-11-18
• Last updated: 2025-11-18

Locations

1 site across 1 country: China